Lurbinectedin Plus Doxorubicin Shows Early Efficacy and Safety in Soft Tissue Sarcomas

A full dose of lurbinectedin plus a low dose of doxorubicin was clinically active and tolerable in patients with advanced or metastatic soft tissue sarcomas, supporting its continued investigation in those with leiomyosarcoma.

Related Keywords

Massachusetts ,United States ,Japan ,Kronos Bio ,Gregory Michael Cote ,Sumitomo Dainippon Pharma ,Stephanl Harris Center ,Cancer Center ,Jazz Pharmaceuticals ,Harvard Medical School ,Belinda Termeer Center ,Merck Kgaa ,Merck Kga ,Massachusetts General Hospital ,Targeted Therapies ,Connective Tissue Oncology ,Harvard Medical ,Foghorn Therapeutics ,Bavarian Nordic ,Ikena Oncology ,Brain Therapeutics ,Repare Therapeutics ,Springworks Therapeutics ,